Tamas Hickish

Tamas Hickish

  • thickish at bournemouth dot ac dot uk
Back to top

Biography

Consultant Medical Oncologist, Dorset Cancer Centre c/o Royal Bournemouth Hospital Visiting Professor Bournemouth University Medical Director iQHealth Tech

Research

Point of Care testing using pin prick blood testing for neutrophil count in patients receiving chemotherapy.

Exploring AI/Machine learning to interogate ECHO data in patients receiving Trastuzumab.

Journal Articles

  • Gögenur, M., Hickish, T. et al., 2024. Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy Post Hoc Analysis of the SCOT Randomized Clinical Trial. JAMA Surgery, 159 (8), 865-871.
  • Glasbey, J. et al., 2024. Risk of Bowel Obstruction in Patients Undergoing Neoadjuvant Chemotherapy for High-risk Colon Cancer: A Nested Case-control-matched Analysis of an International, Multicenter, Randomized Controlled Trial (FOxTROT). Annals of Surgery, 280 (2), 283-293.
  • Abraham, J.E., Hickish, T. et al., 2024. The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. Nature, 629 (8014), 1142-1148.
  • Holt, S., Hickish, T. et al., 2024. A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer. British Journal of Cancer, 130 (7), 1149-1156.
  • Coakley, M., Hickish, T. et al., 2024. Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research, 30 (4), 895-903.
  • Turner, N.C., Hickish, T. et al., 2023. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Annals of Oncology, 34 (2), 200-211.
  • Ring, A., Hickish, T. et al., 2023. Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010). Clinical Cancer Research, 29 (23), 4751-4759.
  • Geyer, C.E. et al., 2022. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Annals of Oncology, 33 (12), 1250-1268.
  • Hickish, T. et al., 2022. Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial. Breast Cancer Research and Treatment, 192 (3), 593-602.
  • Tutt, A.N.J. et al., 2021. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med, 384 (25), 2394-2405.
  • Pritchard, C., Birch, B., Hickish, T. and Rosenorn-Lanng, E., 2021. Comparing Total Neoplasms, Breast & Prostate Cancer Mortality Rates of the UK and 20 Major Developed Countries 1989-91 v 2013- 15 - Identifying Progress. Archive Internal Medical Research, 4 (1), 19-30.
  • Bridgewater, J.A., Hickish, T. et al., 2020. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. The Lancet Oncology, 21 (3), 398-411.
  • Mansbridge, C., Simmonds, P., Murray, N., Davies, A., Stanton, L., Chinnery, F., Archer, C., Barrett-Lee, P., Hickish, T. and Crabb, S., 2020. A phase 2 open-label study of carboplatin in combination with gemcitabine as a dose-dense schedule in patients with locally advanced or metastatic breast cancer that are resistant to anthracyclines and taxanes. F1000Research, 9.
  • Ivesono, T., Hickish, T. et al., 2019. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage ii and iii colorectal cancer: 3-year follow-up of the scot non-inferiority rct. Health Technology Assessment, 23 (64), 1-88.
  • Jones, R.P. et al., 2019. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA Surg, 154 (11), 1038-1048.
  • Huober, J., Hickish, T. et al., 2019. Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. European Journal of Cancer, 118, 169-177.
  • Auclin, E., André, T., Taieb, J., Banzi, M., Van Laethem, J.L., Tabernero, J., Hickish, T., de Gramont, A. and Vernerey, D., 2019. Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial. British Journal of Cancer, 121 (4), 312-317.
  • Primrose, J.N., Hickish, T. et al., 2019. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet Oncology, 20 (5), 663-673.
  • Kurzrock, R., Hickish, T., Wyrwicz, L., Saunders, M., Wu, Q., Stecher, M., Mohanty, P., Dinarello, C.A. and Simard, J., 2019. Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer. OncoImmunology, 8 (3).
  • Auclin, E., Hickish, T. et al., 2019. Carcinoembryonic antigen levels and survival in stage III colon cancer: Post hoc analysis of the MOSAIC and PETACC-8 trials. Cancer Epidemiology Biomarkers and Prevention, 28 (7), 1153-1161.
  • Robles-Zurita, J., Hickish, T. et al., 2018. SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. British Journal of Cancer, 119 (11), 1332-1338.
  • Cidon, E.U., Martinez, P.A. and Hickish, T., 2018. Gemcitabine-induced haemolytic uremic syndrome, although infrequent, can it be prevented: A case report and review of literatureN. World Journal of Clinical Cases, 6 (12), 531-537.
  • Jankowski, J.A.Z. et al., 2018. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. Lancet, 392 (10145), 400-408.
  • Iveson, T.J., Hickish, T. et al., 2018. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. The Lancet Oncology, 19 (4), 562-578.
  • Pritchard, C., Williams, R., Hickish, T. and Wallace, M., 2018. A Population-Based Study Comparing Child (0-4) and Adult (55-74) Mortality, GDP-Expenditure on-Health and Relative Poverty in the UK and Developed Countries 1989-2014. Some Challenging Outcomes. Archives of Community Medicine and Public Health, 3 (2), 77-84.
  • Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Waldron-Lynch, M., Eng-Wong, J., Kirk, S. and Cortés, J., 2018. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. European Journal of Cancer, 89, 27-35.
  • McLaughlin, P., Mactier, H., Gillis, C., Hickish, T., Parker, A., Liang, W.J. and Osselton, M.D., 2017. Increased DNA Methylation of ABCB1, CYP2D6, and OPRM1 Genes in Newborn Infants of Methadone-Maintained Opioid-Dependent Mothers. Journal of Pediatrics, 190, 180-184.e1.
  • Emile, J.F. et al., 2017. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. European Journal of Cancer, 82, 16-24.
  • Gligorov, J. et al., 2017. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. European Journal of Cancer, 82, 237-246.
  • Wasan, H.S., Hickish, T. et al., 2017. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. The Lancet Oncology, 18 (9), 1159-1171.
  • Earl, H.M., Hickish, T. et al., 2017. Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis trial. Annals of Oncology, 28 (8), 1817-1824.
  • Thomas, J.S.J., Hickish, T. et al., 2017. Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial. Modern Pathology, 30 (8), 1069-1077.
  • Davidson, M., Chau, I., Cunningham, D., Khabra, K., Iveson, T., Hickish, T., Seymour, M. and Starling, N., 2017. Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. World Journal of Gastrointestinal Oncology, 9 (8), 333-340.
  • Earl, H.M., Hickish, T. et al., 2017. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. LANCET ONCOLOGY, 18 (6), 755-769.
  • Kurzrock, R. et al., 2017. Pre-treatment endogenous interleukin-1 receptor antagonist (IL-1Ra) levels in metastatic colorectal cancer (mCRC) patients are associated with clinical outcomes after anti-interleukin-1a therapy (MABp1). Annals of oncology : official journal of the European Society for Medical Oncology, 28, iii98-iii99.
  • Una Cidon, E., Alonso, P. and Hickish, T., 2017. Sensitivity and specificity of DPD deficiency screening test to predict capecitabine serious toxicities. Annals of oncology : official journal of the European Society for Medical Oncology, 28, iii119-iii120.
  • Middleton, G., Hickish, T. et al., 2017. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. The Lancet Oncology, 18 (4), 486-499.
  • Hickish, T. et al., 2017. MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology, 18 (2), 192-201.
  • Pugh, S.A., Hickish, T. et al., 2016. Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. British Journal of Cancer, 115 (4), 420-424.
  • Pritchard, C., Hickish, T., Rosenorn-Lanng, E. and Wallace, M., 2016. Comparing UK and 20 Western countries' efficiency in reducing adult (55-74) cancer and total mortality rates 1989-2010: Cause for cautious celebration? A population-based study. JRSM Open, 7 (6), 2054270416635036.
  • Saunders, E.J. et al., 2016. Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. Br J Cancer, 114 (8), 945-952.
  • Ali, H.R., Hickish, T. et al., 2016. Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Research, 18 (1).
  • André, T., Hickish, T. et al., 2015. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: Updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. Journal of Clinical Oncology, 33 (35), 4176-4187.
  • Sclafani, F., Hickish, T. et al., 2015. Short- and long-term quality of life and bowel function in patients with MRI-defined, high-risk, locally advanced rectal cancer treated with an intensified neoadjuvant strategy in the randomized phase 2 EXPERT-C trial. International Journal of Radiation Oncology Biology Physics, 93 (2), 303-312.
  • Amin Al Olama, A. et al., 2015. Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Hum Mol Genet, 24 (19), 5589-5602.
  • Primrose, J.N., Hickish, T. et al., 2015. Cetuximab is contraindicated in the perioperative treatment of colorectal liver metastases. Journal of Clinical Oncology, 33 (21), 2405-2406.
  • Earl, H.M., Hickish, T. et al., 2015. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol, 16 (6), 656-666.
  • Earl, H. et al., 2015. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncology.
  • Abbey, G., Thompson, S.B.N., Heathcote, D. and Hickish, T., 2015. A meta-analysis of prevalence and moderating factors data for cancer-related post-traumatic stress disorder. Psych-Oncology, Volume 24, Issue 4 April 2015 Pages 371–381 (4), 7-7.
  • PETACC-8 study investigators, Hickish, T. et al., 2015. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. Ann Oncol, 26 (4), 822-825.
  • Purandare, L. and Hickish, T., 2015. Acceptability and safety of telemedicine to assess patients before chemotherapy. Cancer Nursing Practice, 14 (6), 20-24.
  • Gillis, C., McLaughlin, P., Osselton, D., Hickish, T. and Mactier, H., 2015. Genetic and epigenetic variations and gene methylation in infants exposed to methadone in-utero. British Association of Perinatal Medicine; Arch Dis Child.
  • Sclafani, F., Hickish, T. et al., 2014. Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. International Journal of Radiation Oncology Biology Physics.
  • Mishu, M., Dubey, V.N., Hickish, TH and Cole, J., 2014. A Review on Pressure Ulcer: Aetiology, Cost, Detection and Prevention Systems. International Journal of Engineering Sciences & Research Technology, 3 (9), 419-428.
  • Middleton, G., Hickish, T. et al., 2014. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol, 15 (8), 829-840.
  • Taieb, J. et al., 2014. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol, 15 (8), 862-873.
  • Masters, B., Hickish, T. and Cidon, E.U., 2014. A midline for oxaliplatin infusion: the myth of safety devices. BMJ Case Rep, 2014.
  • Mishu, M.C., Dubey, V.N., Hickish, T. and Cole, J., 2014. Mathematical Modelling of Different Types of Body Support Surface for Pressure Ulcer Prevention. International Journal of Medical, Pharmaceutical Science and Engineering, 8 (5), 209-214.
  • Yao, C., Nash, G.F. and Hickish, T., 2014. Management of colorectal cancer and diabetes. J R Soc Med, 107 (3), 103-109.
  • Molife, L.R., Hickish, T. et al., 2014. Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncol, 10 (2), 219-231.
  • Earl, H.M., Hickish, T. et al., 2014. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial. Lancet Oncol, 15 (2), 201-212.
  • Pan, J.J., Chang, J., Yang, X., Zhang, J.J., Qureshi, T., Howell, R., Hickish, T. and Liang, H., 2014. Virtual reality training and assessment in laparoscopic rectum surgery. International Journal of Medical Robotics and Computer Assisted Surgery.
  • Primrose, J., Hickish, T. et al., 2014. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: The New EPOC randomised controlled trial. The Lancet Oncology, 15 (6), 601-611.
  • Hickish, T. et al., 2014. A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. European Journal of Cancer, 50, 3136-3144.
  • Wasan, H. et al., 2014. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncology, 15 (6), 631-639.
  • Hickish, T. et al., 2014. A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. European Journal of Cancer, 50, 3136-3144.
  • Schneeweiss, A., Hickish, T. et al., 2013. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol, 24 (9), 2278-2284.
  • Awada, A., Hickish, T. et al., 2013. The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or triple negative obreast cancer (TNBC). CANCER RESEARCH, 73.
  • Agbamu, D.A., Hickish, T.F.G. et al., 2012. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: The pilot phase of a randomised controlled trial. The Lancet Oncology, 13 (11), 1152-1160.
  • Hickish, T. and Farmery, A.D., 2012. Acid-base physiology: New concepts. Anaesthesia and Intensive Care Medicine, 13 (11), 567-572.
  • Nash, G.F., Turner, K.J., Hickish, T., Smith, J., Chand, M. and Moran, B.J., 2012. Interactions in the aetiology, presentation and management of synchronous and metachronous adenocarcinoma of the prostate and rectum. Ann R Coll Surg Engl, 94 (7), 456-462.
  • Tournigand, C., Hickish, T. et al., 2012. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol, 30 (27), 3353-3360.
  • Dunlop, M.G. et al., 2012. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nature Genetics, 44 (7), 770-776.
  • Lin, N.U., Hickish, T. et al., 2012. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Research and Treatment, 133 (3), 1057-1065.
  • Dunlop, M.G. et al., 2012. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet, 44 (7), 770-776.
  • Moyers-Ruiz, L., Hickish, T. and Thompson, S.B.N., 2012. Prospective and working memory decline as a result of impaired sleep and/or impaired blood glucose in breast cancer patients during chemotherapy treatment. Journal of Clinical Oncology, 30 ((Suppl), abstr), TPS9148.
  • James, N.D. et al., 2012. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med, 366 (16), 1477-1488.
  • Baselga, J. et al., 2012. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, 379 (9816), 633-640.
  • Moyers-Ruiz, L., Thompson, S. and Hickish, T., 2012. Investigation Of Prospective And Working Memory Decline And The Impact Of Impaired Sleep And/Or Glucose Metabolism In Recently Diagnosed Breast Cancer Patients Undergoing Chemotherapy: A Longitudinal Study. PSYCHO-ONCOLOGY, 21, 6.
  • Moyers-Ruiz, L., Hickish, T. and Thompson, S.B.N., 2012. Prospective and working memory decline as a result of impaired sleep and/or impaired blood glucose in breast cancer patients during chemotherapy treatment. Journal of Clinical Oncology, 30 (Suppl), TPS9148.
  • Schroeder, J., Dubey, V., Hickish, T. and Cole, J., 2012. Wearable Electrocutaneous Feedback System: A Smart Device to Compensate for Sensation Loss. Journal of Medical Devices, 6 (1).
  • Schroeder, J., Dubey, V., Hickish, T. and Cole, J., 2012. Case Study on Repeatability of a Threshold-Based Calibration Method for Electrocutaneous Feedback Systems. Journal of Medical Devices, 6 (1).
  • Chirgwin, J. et al., 2012. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Res Treat, 131 (1), 295-306.
  • Regan, M.M. et al., 2011. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol, 12 (12), 1101-1108.
  • Thompson, S., Eccleston, L. and Hickish, T.F., 2011. Post-traumatic stress disorder on cancer survivors: recognising and acknowledging the symptoms. WMC Oncology, 2, 1-16.
  • Adams, R.A., Hickish, T. et al., 2011. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol, 12 (7), 642-653.
  • Maughan, T.S. et al., 2011. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet, 377 (9783), 2103-2114.
  • Seymour, M.T. et al., 2011. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet, 377 (9779), 1749-1759.
  • Seymour, M.T., Hickish, T. et al., 2011. Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). J Clin Oncol, 29 (15_suppl), 3523.
  • Pritchard, C. and Hickish, T.F., 2011. Cancer survival in Australia, Canada, Denmark, Norway, Sweden and the UK. Lancet, 377, 1149.
  • Pritchard, C. and Hickish, T.F., 2011. Comparing cancer mortality and GDP health expenditure in England and Wales with other major developed countries from 1979 to 2006. British Journal of Cancer.
  • Pan, J., Chang, J., Yang, X., Zhang, J.J., Qureshi, T. and Howell, R., 2011. A Medical VR Simulator in Laparoscopic Rectum Surgery. Cyber Therapy and Rehabilitation, 4, 19-20.
  • Valle, J. et al., 2010. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med, 362 (14), 1273-1281.
  • Houston, S., Grieve, R.J., Hickish, T.F., Percival, F. and Hamilton, E., 2010. Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study. Journal of Medical Economics, 13, 162-167.
  • Sirohi, B., Hickish, T.F. et al., 2010. A randomized comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial. Annals of Oncology, 21, 1623-1629.
  • Cunningham, D. and Hickish, T.F., 2010. A multicentre phase II study of capecitabine, oxaliplatin plus bevacizumab as peri-operative treatment for patients with poor risk colorectal liver-only metastases unsuitable for upfront resection. Journal of Clinical Oncology.
  • Pan, J., Chang, J., Yang, X., Zhang, J., Qureshi, T., Howell, R.D. and Hickish, T.F., 2010. Graphic and haptic simulation system for virtual laparoscopic rectum surgery. International Journal of Medical Robotics and Computer Assisted Surgery, 7.
  • Teixeira, L., Hickish, T., Tournigand, C., Bachet, J., Bonetti, A., Rivera, F., Boni, C., Tabernero, J., Andre, T. and De Gramont, A., 2010. Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors. JOURNAL OF CLINICAL ONCOLOGY, 28 (15).
  • Toumigand, C., Andre, T., Bachet, J., Teixeira, L., Boni, C., Clingan, P.R., Hickish, T., Tabernero, J. and De Gramont, A., 2010. FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): Subgroup analysis of the MOSAIC trial. JOURNAL OF CLINICAL ONCOLOGY, 28 (15).
  • Al Olama, A.A. et al., 2009. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet, 41 (10), 1058-1060.
  • Eeles, R.A. et al., 2009. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet, 41 (10), 1116-1121.
  • BIG 1-98 Collaborative Group et al., 2009. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med, 361 (8), 766-776.
  • Giobbie-Hurder, A., Price, K.N., Gelber, R.D., International Breast Cancer Study Group and BIG 1-98 Collaborative Group, 2009. Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clin Trials, 6 (3), 272-287.
  • Hickish, T., Wheatley, D., Lin, N., Carey, L., Houston, S., Mendelson, D., Solca, F., Uttenreuther-Fischer, M., Jones, H. and Winer, E., 2009. Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. J Clin Oncol, 27 (15_suppl), 1023.
  • Earl, H.M., Hickish, T. et al., 2009. Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR). J Clin Oncol, 27 (15_suppl), 522.
  • Ellis, P. et al., 2009. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet, 373 (9676), 1681-1692.
  • Chau, I., Norman, A.R., Cunningham, D., Oates, J., Hawkins, R., Iveson, T., Nicolson, M., Harper, P., Seymour, M. and Hickish, T., 2009. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol, 20 (5), 885-891.
  • Hickish, T.F., Astras, G., Thomas, P., Penfold, S., Purandare, L. and Kerr, D., 2009. Glucose intolerance during adjuvant chemotherapy for breast cancer. Correspondence. Journal of the National Cancer Institute, 101, 537.
  • Andre, T., Hickish, T.F. et al., 2009. Improved overall survival with oxaliplatin, fluorouracil and leucovorin as adjuvant treatment in stage II / III colon cancer: update from a randomised controlled trial. Journal of Clinical Oncology, 27, 3109-3116.
  • Boni, C., Andre, T., Banzi, M.C., Hickish, T.F., Tabernero, J., Clingan, P., Chibaudel, B. and De Gramont, A., 2009. Similarities and differences between the adjuvant oxaliplatin-based trials, MOSAIC and NSABP C-07. Current Colorectal Cancer Reports, 5, 166-170.
  • Viale, G. et al., 2008. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol, 26 (34), 5569-5575.
  • Pritchard, C. and Hickish, T.F., 2008. Changes in Cancer Incidence and Mortality in England & Wales and a comparison of cancer deaths in the Major Developed Countries by Age and Sex 1979-2002 in context of GDP Expenditure on Health. ecancermedicalscience, 2, 1-18.
  • Hemandas, A.K., Robson, N.K., Hickish, T.F. and Talbot, R.W., 2008. Colorectal tubulovillous adenomas identified on fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography scans. Colorectal Disease, 10, 386-389.
  • Chand, M., Moore, P.J., Clarke, A.D., Nash, G.F. and Hickisk, T., 2007. A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation - A case report of primary papillary serous carcinoma presenting as sigmoid cancer. World Journal of Surgical Oncology, 5.
  • Hickish, T., Chau, I., Massey, A., Higgins, L., Osborne, R., Botwood, N., Swaisland, A. and Cunningham, D.C., 2006. Gefitinib and irinotecan in patients with fluoropyrimidine-refractory irinotecan-naïve advanced colorectal cancer (CRC): dose-finding, pharmacokinetics, safety and efficacy. J Clin Oncol, 24 (18_suppl), 13520.
  • Cassidy, J., Bjarnason, G.A., Hickish, T., Topham, C., Provencio, M., Bodoky, G., Landherr, L., Koralewski, P., Lopez-Vivanco, G. and Said, G., 2006. Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). J Clin Oncol, 24 (18_suppl), 3507.
  • Chau, I., Hickish, T.F. et al., 2006. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. British Journal of Cancer, 94, 1107-1115.
  • Trumper, M., Ross, P.J., Cunningham, D., Norman, A.R., Hawkins, R., Seymour, M.T.J., Harper, P., Iveson, T.J., Nicolson, M.C. and Hickish, T.F., 2006. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. European Journal of Cancer, 42, 827-834.
  • Hickish, T.F., 2006. Administration of cetuximab in managing colorectal cancer. Cancer Nursing Practice, 5, 28-29.
  • Chau, I., Cunningham, D., Hickish, T.F., Massey, A., Higgins, L., Osborne, R.J., Botwood, N. and Swaisland, A., 2006. Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. Annals of Oncology, 18, 730-737.
  • Chau, I., Hickish, T.F. et al., 2005. Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. European Journal of Cancer, 41, 1551-1559.
  • Chua, S., Hickish, T.F. et al., 2005. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Annals of Oncology, 16, 1435-1441.
  • Sumpter, K., Hickish, T.F. et al., 2005. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. British Journal of Cancer, 92, 1976-1983.
  • Chau, I., Hickish, T. et al., 2005. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol, 16 (4), 549-557.
  • Mandalà, M., Ferretti, G., Barni, S., De Gramont, A., André, T. and Hickish, T., 2004. Oxaliplatin in colon cancer [3] (multiple letters). New England Journal of Medicine, 351 (16), 1691-1692.
  • Starling, N., Chau, I., Norman, A.R., Tait, D., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D. and Cunningham, D., 2004. A randomised comparison between six months of bolus fluorouracil (5-FU)/leucovorin (LV) and twelve weeks of protracted venous infusion (PVI) 5-FU as adjuvant treatment in colorectal cancer: An update with 5 years' follow-up. J Clin Oncol, 22 (14_suppl), 3523.
  • Trumper, M.J., Norman, A.R., Ross, P.J., Cunningham, D., Hawkins, R., Seymour, M., Harper, P., Iveson, T., Nicholson, M. and Hickish, T., 2004. Patients aged 70 or older (≥ 70) with advanced oesophagogastric cancer (OGC) experience similar benefits from palliative chemotherapy compared to younger patients. J Clin Oncol, 22 (14_suppl), 4018.
  • Hickish, T., Boni, C., Navarro, M., Tabernero, J., Topham, C., Bonetti, A., Clingan, P., Figer, A., Andre, T. and De Gramont, A., 2004. FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): Subpopulation data from the MOSAIC trial. J Clin Oncol, 22 (14_suppl), 3619.
  • Norman, A.R., Chau, I., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D., Shellito, P., Oates, J. and Cunningham, D., 2004. Longitudinal quality of life (QoL) and quality adjusted survival (QAS) in a randomised controlled trial (RCT) comparing bolus (24 weeks) vs. protracted venous infusion (PVI 12 weeks) 5-FU as adjuvant chemotherapy for colorectal cancer (CRC). J Clin Oncol, 22 (14_suppl), 3625.
  • Andre, T., Hickish, T.F. et al., 2004. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. New England Journal of Medicine, 350, 2343-2351.
  • Papazisis, K.T., Hickish, T. et al., 2004. Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK. International Journal of Clinical Practice, 58 (6), 581-586.
  • Smith, I.E., Hickish, T.F. et al., 2004. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Annals of Oncology, 15, 751-758.
  • Price, T.J., Hickish, T.F. et al., 2004. Phase III Study of Mitomycin-C with Protracted Venous Infusion or Circadian-Timed Infusion of 5-Fluorouracil in Advanced Colorectal Carcinoma. Clinical Colorectal Cancer, 3, 235-242.
  • O'Brien, M.E.R., Hickish, T. et al., 2004. SRL 172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: Phase III results. Annals of Oncology, 15 (6), 906-914.
  • Hickish, T., Boni, C., Navarro, M., Tabernero, J., Bonetti, A., Clingan, P., Figer, A., Andre, T. and de Gramont, A., 2004. Stage II patients in the "MOSAIC" trial evaluating Oxaliplatin/5FU/LV as adjuvant treatment of colon cancer: a subpopulation analysis. ANNALS OF ONCOLOGY, 15, 76.
  • Ross, P.J., Trumper, M., Norman, A.R., Hawkins, R., Seymour, M., Harper, P.G., Iveson, T., Nicolson, M., Hickish, T. and Cunningham, D., 2004. An analysis of the outcome to palliative chemotherapy for oesophagogastric (OGC) cancer in patients aged 70 years and older (≥70) with younger patients. ANNALS OF ONCOLOGY, 15, 230.
  • de Gramont, A., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Marceau-Suissa, J. and Andre, T., 2004. Oxaliplatin/5FU/LV in stage II and III Colon Cancer: Updated results (as of January 04) for efficacy and neurotoxicity of the MOSAIC trial. ANNALS OF ONCOLOGY, 15, 73.
  • Saini, A., Hickish, T.F. et al., 2003. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. British Journal Of Cancer, 88, 1859-1866.
  • Assersohn, L., Norman, A.R., Cunningham, D., Iveson, T.J., Seymour, M.T.J., Hickish, T.F., Massey, A., Prior, Y. and Hilla, M.E., 2003. A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary. European Journal of Cancer, 39, 1121-1128.
  • Johnston, S.R.D. et al., 2003. Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast Cancer. Journal of Clinical Oncology, 21, 2492-2499.
  • Maisey, N.R., Hickish, T.F. et al., 2002. Multicenter Randomized Phase III Trial Comparing Protracted Venous Infusion (PVI) Fluorouracil (5-FU) With PVI 5-FU Plus Mitomycin in Inoperable Pancreatic Cancer. Journal of Clinical Oncology, 20, 3130-3136.
  • Ross, P.J., Hickish, T.F. et al., 2002. Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer. Journal of Clinical Oncology, 20, 1996-2004.
  • Tebbutt, N.C., Hickish, T. et al., 2002. A muticentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Annals of Oncology, 13 (10), 1568-1575.
  • Dowsett, M., Cuzick, J., Howell, A., Jackson, I. and ATAC Trialists' Group, 2001. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. Br J Cancer, 85 (3), 317-324.
  • Donnelly, J., Parham, D.M., Hickish, T.F., Chan, H.Y. and Skene, A.I., 2001. Axillary lymph node scarring and the association with tumour response following neoadjuvant chemoendocrine therapy for breast cancer. The Breast, 10, 61-66.
  • Smith, I.E., O Brien, M.E.R., Talbot, D.C., Nicolson, M.C., Mansi, J.L., Hickish, T.F., Norton, A. and Ashley, S., 2001. Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin. Journal of Clinical Oncology, 19, 1336-1343.
  • Smith, I.E., Johnston, S.R.D., O Brien, M.E.R., Hickish, T.F., de Boer, R.H., Norton, A., Cirkel, D.T. and Barton, C.M., 2000. Low-Dose Oral Fluorouracil With Eniluracil as First-Line Chemotherapy Against Advanced Breast Cancer: A Phase II Study. Journal of Clinical Oncology, 18, 2378-2384.
  • Smith, I.E., A'Hern, R.P., Ebbs, S., Howell, A., Hickish, T., O'Brien, M., Robinson, A. and Wilson, C., 2000. Preoperative continuous infusional (epirubicin, cisplatin and infusional 5 FU) v. conventional AC chemotherapy for early breast cancer: As phase III randomised trial. BRITISH JOURNAL OF CANCER, 83, 2.
  • Iveson, T.J., Hickish, T., Schmitt, C. and Van Cutsem, E., 1999. Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. Eur J Cancer, 35 (13), 1796-1804.
  • Waters, J.S., Hickish, T. et al., 1999. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer, 80 (1-2), 269-272.
  • Ross, P., Hickish, T. et al., 1999. Results of a randomised trial comparing ECF with MCF in advanced oesophago-gastric cancer. EUROPEAN JOURNAL OF CANCER, 35, S137.
  • Price, T., Cunningham, D., Hickish, T., Tait, D., Norman, A., Ross, P.J., Middleton, G., Ford, H.E.R., Sumpter, K. and Hill, M., 1999. Dose intensification of 5 fluorouracil by chronomodulation in a phase III trial for advanced colorectal carcinoma. BRITISH JOURNAL OF CANCER, 80, 20.
  • Middleton, G.W., Smith, I.E., O'Brien, M.E.R., Norton, A., Hickish, T., Priest, K. and Spencer, L., 1998. Good symptom relief with palliative MVP mitomycin-C, vinblastine and cisplatin chemotherapy in malignant mesothelioma. Pneumologie, 52 (7), 432.
  • Makris, A., Powles, T.J., Ashley, S.E., Chang, J., Hickish, T., Tidy, V.A., Nash, A.G. and Ford, H.T., 1998. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol, 9 (11), 1179-1184.
  • Cunningham, D., Hickish, T.F. et al., 1998. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 352 (9138), 1413-1418.
  • Cunningham, D., Hickish, T. et al., 1998. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol, 102 (2), 495-502.
  • Middleton, G.W., Smith, I.E., O'Brien, M.E., Norton, A., Hickish, T., Priest, K., Spencer, L. and Ashley, S., 1998. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol, 9 (3), 269-273.
  • Beale, P., Judson, I., Hanwell, J., Berry, C., Aherne, W., Hickish, T., Martin, P. and Walker, M., 1998. Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients. Cancer Chemother Pharmacol, 42 (1), 71-76.
  • Hickish, T.F., Smith, I.E., Nicolson, M.C., Ashley, S., Priest, K., Spencer, L., Norman, A., Middleton, G. and O'Brien, M.E.R., 1998. A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer. British Journal of Cancer, 77 (11), 1966-1970.
  • Hickish, T.F., Smith, I.E., O'Brien, M.E.R., Ashley, S. and Middleton, G., 1998. Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors. British Journal of Cancer, 78 (1), 28-33.
  • Iveson, T., Eggleton, S.P.H., Hickish, T., Cunningham, D., Maughan, T. and Harper, P., 1998. Irinotecan (CPT-11) in 5-FU pretreated advanced colorectal cancer: Results in 174 expanded access patients. ANNALS OF ONCOLOGY, 9, 36-37.
  • Mattia, E., Chichiarelli, S., Hickish, T., Gaeta, A., Mancini, C., Cunningham, D. and van Renswoude, J., 1997. Inhibition of in vitro proliferation of Epstein Barr Virus infected B cells by an antisense oligodeoxynucleotide targeted against EBV latent membrane protein LMP1. Oncogene, 15 (4), 489-493.
  • Webb, A., Hickish, T. et al., 1997. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol, 15 (1), 261-267.
  • Mainwaring, P.N., Nicolson, M.C., Hickish, T., Penson, R., Joel, S., Slevin, M. and Smith, I.E., 1997. Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy. Br J Cancer, 76 (12), 1636-1639.
  • Hickish, T.F., Smith, I.E., Ashley, S. and Middleton, G., 1996. Chemotherapy for elderly patients with lung cancer. Pneumologie, 50 (7), 503.
  • O'Brien, M.E., Milan, S., Cunningham, D., Jones, A.L., Nicolson, M., Selby, P., Hickish, T., Hill, M., Gore, M.E. and Viner, C., 1996. High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index. Br J Cancer, 73 (10), 1272-1277.
  • Powles, R., Raje, N., Horton, C., Mehta, J., Singhal, S., Hickish, T., Viner, C., Milan, S., Treleaven, J. and Cunningham, D., 1996. Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy. Leuk Lymphoma, 21 (5-6), 421-427.
  • Findlay, M., Young, H., Cunningham, D., Iveson, A., Cronin, B., Hickish, T., Pratt, B., Husband, J., Flower, M. and Ott, R., 1996. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol, 14 (3), 700-708.
  • Modjtahedi, H. et al., 1996. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer, 73 (2), 228-235.
  • Powles, T.J., Hickish, T., Kanis, J.A., Tidy, A. and Ashley, S., 1996. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol, 14 (1), 78-84.
  • Nicolson, M., Webb, A., Cunningham, D., Norman, A., O'Brien, M., Hill, A. and Hickish, T., 1995. Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma. Ann Oncol, 6 (8), 801-804.
  • Powles, T.J. and Hickish, T., 1995. Tamoxifen therapy and carcinogenic risk. J Natl Cancer Inst, 87 (18), 1343-1345.
  • Hill, M., Norman, A., Cunningham, D., Findlay, M., Watson, M., Nicolson, V., Webb, A., Middleton, G., Ahmed, F. and Hickish, T., 1995. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol, 13 (9), 2317-2323.
  • Hickish, T.F., Smith, I.E., Ashley, S. and Middleton, G., 1995. Chemotherapy for elderly patients with lung cancer. The Lancet, 346 (8974), 580.
  • Powles, T.J. and Hickish, T., 1995. Breast cancer response to hormone replacement therapy withdrawal. Lancet, 345 (8962), 1442.
  • Eisen, T., Hickish, T., Smith, I.E., Sloane, J. and Eccles, S., 1995. Small-cell lung cancer. Report of a Meeting of POhysicians and Scientists at the Royal Marsden Hospital, Sutto, UK. The Lancet, 345 (8960), 1285-1289.
  • Hickish, T.F., Smith, I.E., Mlddleton, G. and Nicolson, M., 1995. Patient preference for extended palliative chemotherapy for non-small cell lung cancer. The Lancet, 345 (8953), 857-858.
  • Hill, M., Hickish, T. et al., 1995. Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity. Journal of Clinical Oncology, 13 (2), 387-395.
  • Hill, M., Hickish, T. et al., 1995. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. Journal of Clinical Oncology, 13 (6), 1297-1302.
  • Powles, T.J. et al., 1995. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. Journal of Clinical Oncology, 13 (3), 547-552.
  • Ellis, P.A., Norman, A., Hill, A., O'Brien, M.E.R., Nicolson, M., Hickish, T. and Cunningham, D., 1995. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. European Journal of Cancer, 31 (10), 1594-1598.
  • McMaster, T.J., Hickish, T., Min, T., Cunningham, D. and Miles, M.J., 1994. Application of scanning force microscopy to chromosome analysis. Cancer Genet Cytogenet, 76 (2), 93-95.
  • Findlay, M., Cunningham, D., Norman, A., Mansi, J., Nicolson, M., Hickish, T., Nicolson, V., Nash, A., Sacks, N. and Ford, H., 1994. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol, 5 (7), 609-616.
  • Hickish, T.F. and Cunningham, D., 1994. Should induction chemotherapy be considered for all patients with gastric cancer? European Journal of Surgical Oncology, 20 (2), 185-186.
  • Hickish, T., Robertson, D., Clarke, P., Hill, M., di Stefano, F., Clarke, C. and Cunningham, D., 1994. Ultrastructural localization of BHRF1: an Epstein-Barr virus gene product which has homology with bcl-2. Cancer Res, 54 (10), 2808-2811.
  • Cunningham, D., Paz-Ares, L., Milan, S., Powles, R., Nicolson, M., Hickish, T., Selby, P., Treleavan, J., Viner, C. and Malpas, J., 1994. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol, 12 (4), 759-763.
  • Cunningham, D., Paz-Ares, L., Gore, M.E., Malpas, J., Hickish, T., Nicolson, M., Meldrum, M., Viner, C., Milan, S. and Selby, P.J., 1994. High-dose melphalan for multiple myeloma: long-term follow-up data. J Clin Oncol, 12 (4), 764-768.
  • McCready, V.R. and Hickish, T.F., 1994. Somatostatin imaging function. The Lancet, 343 (8898), 617.
  • O'Brien, M.E., Matutes, E., Cunningham, D., Hill, M., Emmett, E., Ellis, P.A., Milan, S., Hickish, T., Mercieca, J. and Catovsky, D., 1994. Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience. Leuk Lymphoma, 14 Suppl 2, 17-23.
  • Hill, M., Cunningham, D., MacVicar, D., Roldan, A., Husband, J., McCready, R., Mansi, J., Milan, S. and Hickish, T., 1993. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol, 11 (11), 2273-2278.
  • Hickish, T., Cunningham, D., Colston, K., Millar, B.C., Sandle, J., Mackay, A.G., Soukop, M. and Sloane, J., 1993. The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. Br J Cancer, 68 (4), 668-672.
  • Hickish, T., Roldan, A., Cunningham, D., Mansi, J., Ashley, S., Nicolson, V., Gore, M.E., Catovsky, D. and Smith, I.E., 1993. EPIC: an effective low toxicity regimen for relapsing lymphoma. Br J Cancer, 68 (3), 599-604.
  • Scott-Mackie, P., Hickish, T., Mortimer, P., Sloane, J. and Cunningham, D., 1993. Calcipotriol and regression in T-cell lymphoma of skin. Lancet, 342 (8864), 172.
  • Powles, T.J., Hickish, T., Casey, S. and O'Brien, M., 1993. Hormone replacement after breast cancer. Lancet, 342 (8862), 60-61.
  • HICKISH, T., 1993. 2'-Chlorodeoxyadenosine : evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer, 67, 139-143.
  • Hickish, T.F., Purvies, H., Mansi, J., Soukop, M. and Cunningham, D., 1991. Molecular monitoring of low grade non-hodgkin’s lymphoma by gene amplification. British Journal of Cancer, 64 (6), 1161-1163.
  • Hickish, T. and Cunningham, D., 1990. Gastrointestinal non-Hodgkin's lymphoma. Baillieres Clin Gastroenterol, 4 (1), 191-200.
  • Hickish, T., Colston, K.W., Bland, J.M. and Maxwell, J.D., 1989. Vitamin D deficiency and muscle strength in male alcoholics. Clin Sci (Lond), 77 (2), 171-176.
  • Hickish, T. and Cunningham, D., 1989. Detecting t(14;18) in paraffin-embedded lymphoma tissue. Lancet, 2 (8656), 218-219.
  • Hickish, T. and Cunningham, D., 1989. Detecting t(14;18) in paraffin-embedded lymphoma tissue. Lancet, 1 (8647), 1131-1132.
  • Cunningham, D., Hickish, T., Rosin, R.D., Sauven, P., Baron, J.H., Farrell, P.J. and Isaacson, P., 1989. Polymerase chain reaction for detection of dissemination in gastric lymphoma. Lancet, 1 (8640), 695-697.
  • Hickish, T., Cunningham, D., Haydock, A. and Coombes, R.C., 1989. Experience with intermediate-dose (110-120 mg/m2) epirubicin. Cancer Chemother Pharmacol, 24 (1), 61-64.
  • Hickish, T., Colston, K.W., Bland, J.M. and Maxwell, J.D., 1989. Vitamin D deficiency and muscle strength in male alcoholics. Clinical Science, 77 (2), 177-182.
  • CUNNINGHAM, D., HICKISH, T., ROSIN, R.D., SAUVEN, P., BARON, J.H., FARRELL, P.J. and ISAACSON, P., 1989. POLYMERASE CHAIN-REACTION FOR DETECTION OF DISSEMINATION IN GASTRIC LYMPHOMA. LANCET, 1 (8640), 695-697.
  • HICKISH, T. and CUNNINGHAM, D., 1989. DETECTING T(14-18) IN PARAFFIN-EMBEDDED LYMPHOMA TISSUE. LANCET, 2 (8656), 218-219.
  • HICKISH, T. and CUNNINGHAM, D., 1989. DETECTING T(14-18) IN PARAFFIN-EMBEDDED LYMPHOMA TISSUE. LANCET, 1 (8647), 1131.
  • Isles, S.R., Hickish, T. and Cunningham, D., 1988. Chemotherapy related pulmonary embolus recognized. BMJ, 297 (6652), 854.
  • Smedley, F., Hickish, T., Taube, M., Yale, C., Leach, R. and Wastell, C., 1988. Perforated duodenal ulcer and cigarette smoking. J R Soc Med, 81 (2), 92-94.
  • Smedley, F.H. and Hickish, T., 1986. Non-steroidal anti-inflammatory drugs and peptic ulcer perforation. Gut, 27 (1), 114.

Chapters

  • Cidón, E.U. and Hickish, T., 2014. Stem cells in colon cancer. Stem Cells in Cancer: Should We Believe or Not?. 127-147.

Conferences

  • Thomas, D., Hickish, T. et al., 2020. Impact of the Oncotype DX breast cancer assay on treatment decisions in a UK population of patients with oestrogen receptor positive early breast cancer with 1-3 lymph nodes positive who are candidates for chemotherapy, but for whom the benefits are uncertain - Interim results. CANCER RESEARCH, 80 (4).
  • Cidon, E.U., Alonso, P., Hickish, T., Goulbourne, S. and Tyler, A., 2020. Special mouthwash and chronology of oral mucositis in previous cycle to prevent future episodes. ANNALS OF ONCOLOGY, 31, S128.
  • Jones, R., Hickish, T. et al., 2020. Vandetanib plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER positive breast cancer (FURVA): A randomised, double-blind, placebo-controlled, phase II trial. ANNALS OF ONCOLOGY, 31, S1151.
  • Una Cidon, E., Alonso, P., Hickish, T., Tyler, A. and Goulbourne, S., 2019. Preventing oral mucositis by using its chronology in prior cycle and a special mouthwash. Annals of oncology : official journal of the European Society for Medical Oncology, 30, iv66-iv67.
  • Pogue-Geile, K.L., Hickish, T. et al., 2019. Association of colon cancer (CC) molecular signatures with prognosis and oxaliplatin prediction benefit in the MOSAIC Trial (Multicenter International Study of Oxaliplatin/5FU-LV in the Adjuvant Treatment of Colon Cancer). JOURNAL OF CLINICAL ONCOLOGY, 37 (15).
  • Eccles, B.K., Hickish, T. et al., 2018. Prospective DPYD testing in colorectal cancer patients in a realworld UK population. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii187.
  • Auclin, E., Andre, T., Taieb, J., Banzi, M., van Laethem, J.L., Tabernero, J., Hickish, T., de Gramont, A. and Vernerey, D., 2018. Postoperative carcinoembryonic antigen (CEA) association with survival and oxaliplatin benefit in stage II colon cancer (CC): Post hoc analysis of the MOSAIC trial. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii154.
  • Jeffery, J., Murphy, J.L., Hewitt-Taylor, J. and Hickish, T., 2018. Longitudinal study of energy and macronutrient intake during the first year following treatment for early stage breast cancer. PROCEEDINGS OF THE NUTRITION SOCIETY, 77 (OCE1), E10.
  • Auclin, E., Hickish, T. et al., 2018. Association of postoperative carcinoembryonic antigen (CEA) levels with survival in stage III colon cancer (CC): Post hoc analysis of the MOSAIC and PETACC-8 studies. JOURNAL OF CLINICAL ONCOLOGY, 36 (15).
  • Hickish, T., Mohanty, P., Michael, S., Shivaswamy, S., Sunley, K., Varshney, A., Martin, R. and Simard, J., 2017. Modulation of platelet levels by an anti-IL-1α antibody (MABp1) in advanced colorectal cancer patients. EUROPEAN JOURNAL OF CANCER, 72, S70.
  • Vaughan, N., Dubey, V.N., Hickish, T. and Cole, J., 2017. A smart device to substitute the neurothesiometer. Proceedings of the ASME Design Engineering Technical Conference, 3.
  • Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Waldron-Lynch, M., Eng-Wong, J., Kirk, S. and Cortes, J., 2017. Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA). CANCER RESEARCH, 77.
  • Bridgewater, J., Hickish, T. et al., 2017. Perioperative chemotherapy with or without cetuximab in patients (pts) with resectable colorectal liver metastasis (CRLM): Mature analysis of overall survival (OS) in the New EPOC randomised controlled trial. ANNALS OF ONCOLOGY, 28.
  • Neoptolemos, J.P., Hickish, T. et al., 2017. Biomarker prediction of efficacy to vandetanib plus gemcitabine in a phase II double blind multicenter randomized placebo controlled trial in locally advanced or metastatic pancreatic carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 35.
  • Wyrwicz, L., Hickish, T. et al., 2017. MABp1 to improve clinical outcomes of patients with symptomatic refractory metastatic colorectal cancer patients: Per-protocol population analysis of phase III study (P1026). JOURNAL OF CLINICAL ONCOLOGY, 35.
  • Hickish, T., Andre, T., Wyrwicz, L., Saunders, M., Sarosiek, T., Nemecek, R., Kocsis, J., Stecher, M. and de Gramont, A., 2016. A pivotal phase 3 trial of MABp1 in advanced colorectal cancer. ANNALS OF ONCOLOGY, 27, 128.
  • Earl, H.M., Hickish, T. et al., 2016. Disease-free (DFS) and overall survival (OS) at 3.4 years (yrs) for neoadjuvant bevacizumab (Bev) added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC), for women with HER2 negative early breast cancer: The ARTemis trial. JOURNAL OF CLINICAL ONCOLOGY, 34 (15).
  • Hickish, T. and Purandare, L., 2015. A pilot study to assess the safety and feasibility of pre-chemotherapy assessment using telemedicine. In: Phi Mu Chapter Biannual Conference 19 June 2015 Leeds.
  • Abbey, G., Thompson, S.B.N., Hickish, T. and Heathcote, D., 2015. A meta-analysis of prevalence rates and moderating factors for cancer-related post-traumatic stress disorder. Psycho-Oncology, 24 (4), 371-381.
  • Cidon, E.U., Alonso, P., Needham, S. and Hickish, T., 2015. First cycle dose calculation in obese patients with colorectal cancers. ANNALS OF ONCOLOGY, 26.
  • Earl, H.M., Hickish, T. et al., 2015. ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy for patients with HER2-negative early breast cancer. CANCER RESEARCH, 75.
  • Hickish, Hickish, T. et al., 2014. ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR). In: NCRI Cancer Conference in the Clinical Trials Showcase 2-5 November 2014 Liverpool.
  • Bridgewater, J., Hickish, T. et al., 2014. Analysis of progression free survival in the New EPOC study in an all RAS wild-type population. In: ESMO 2014 Congress 26-30 September 2014 Madrid, Spain.
  • Moyers-Ruiz, L., Thompson, S.B.N., Hickish, T. and Mayers, A., 2014. Prospective memory and cognitive impairment in breast cancer patients. In: 4th International Conference on Prospective Memory 26-30 May 2014 Suor Orsola Benincasa University, Naples.
  • Schroeder, J.W., Dubey, V., Hickish, T. and Cole, T., 2014. Intelligent Agent Based Software Architecture of a Wearable Electrotactile Feedback System for Balance Improvement. In: 2014 International Academic Conference on Engineering, Internet and Technology 12-13 December 2014 Prague. Proceedings of IAC-ElaT 2014.
  • Una Cidon, E., Hickish, T. and Alonso, P., 2014. Cardiac Toxicity with Fluoropyrimidines in Colorectal Cancer. In: ESMO World GI 2014 25-28 June 2014 Barcelona, Spain. Annals of Oncology, 2 (25).
  • Una Cidon, E., Hickish, T. and Alonso, P., 2014. Cetuximab as Monotherapy in Elderly Patients with Metastatic Colorectal Cancer. In: ESMO World GI 2014 25-28 June 2014 Barcelona, Spain. Annals of Oncology, 2 (25).
  • André, T., Hickish, T. et al., 2014. MOSAIC study: Actualization of Overall Survival (OS) with 10 years follow up and evaluation of BRAF by GERCOR and MOSAIC investigators. In: ESMO 2014 26-30 September 2014 Madrid, Spain. Annals of Oncology, 4 (25).
  • Cameron, D., Spector, N., Gomez, H., Hickish, T., Vandat, L., Kim, S.B., Sheldon, E., El-Hariry, I., Perez, E. and Awada, A., 2014. Targeting HSP90 in breast cancer: ENCHANT-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic HER2 positive or triple negative breast cancer (TNBC). EUROPEAN JOURNAL OF CANCER, 50, S98.
  • Schroeder, J.W., Dubey, V., Hickish, T. and Cole, T., 2014. Intelligent Agent Based Software Architecture of a Wearable Electrotactile Feedback System for Balance Improvement. In: International Academic Conference on Engineering, Internet and Technology 12-13 December 2014 Prague. Proceedings of IAC-ElaT 2014.
  • Earl, H., Hickish, T. et al., 2014. ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR). In: NCRI Cancer Conference in the Clinical Trials Showcase 2-5 November 2014 Liverpool.
  • Petricoin, E.F., Wulfkuhle, J., Hickish, T., El-Hariry, I., Reichert, V., Vukovic, V.M., Cameron, D.A., Awada, A. and Spector, N., 2014. Gene expression and proteomic analysis to identify predictive biomarkers of response in the ENCHANT-1 Trial (NCT01677455), a Phase 2 Proof of Concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2 positive or triple negat. CANCER RESEARCH, 74 (19).
  • Abbey, G., Thompson, S.B.N., Hlickish, T. and Heathcota, D., 2014. A meta-analysis of prevalence rates and moderating factors for cancer related post-traumatic stress disorder. JOURNAL OF CLINICAL ONCOLOGY, 32 (15).
  • Cameron, D.A., Hickish, T. et al., 2014. Targeting HSP90 in breast cancer: Enchant-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 32 (15).
  • Moyers-Ruiz, L., Thompson, S.B.N., Hickish, T. and Mayers, A., 2013. Cognitive decline as a result of impaired sleep and glucose levels during chemotherapy treatment in breast cancer patients. In: American Society of Clinical Oncology 31 May-4 June 2013 McCormick Place, Chicago, USA.
  • Flejou, J.-F., Hickish, T. et al., 2013. Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study. JOURNAL OF CLINICAL ONCOLOGY, 31 (15).
  • Primrose, J.N., Hickish, T. et al., 2013. A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study. JOURNAL OF CLINICAL ONCOLOGY, 31 (15).
  • Schroeder, J.W., Dubey, V.N., Hickish, T., Cole, J., Mecheraoui, C. and Swain, I., 2012. Applications of electrical stimulation and electrotactile feedback in human spaceflight. In: 63rd International Astronautical Congress 1-5 October 2012 Naples, Italy.
  • Schroeder, J.W., Dubey, V.N., Hickish, T.F. and Cole, J., 2012. Wearable Electrocutaneous Feed-back System: A Smart Device to Compensate for Sensation Loss. In: Design of Medical Devices 10-12 April 2012 Minneapolis, Minnesota, USA.
  • Schroeder, J.W., Dubey, V.N., Hickish, T.F. and Cole, J., 2012. Case Study on Repeatability of a Threshold-Based Calibration Method for Electrocutaneous Feedback Systems. In: Design of Medical Devices 10-12 April 2012 Minneapolis, Minnesota, USA.
  • Moyers-Ruiz, L., Thompson, S.B.N. and Hickish, T., 2012. Prospective and working memory decline in breast cancer patients during chemotherapy. In: International Cognition & Cancer Task Force 15-17 March 2012 Espace Saint-Martin, Paris, France.
  • Moyers-Ruiz, L., Thompson, S.B.N. and Hickish, T., 2012. Longitudinal study of prospective and working memory decline in breast cancer patients undergoing chemotherapy. In: British Psychosocial Oncology Society Annual Conference 19-20 January 2012 Metropole Hotel, Leeds.
  • Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Hegg, R., Tausch, C., Seo, J.H., Tsai, Y.F., McNally, V. and Cortes, J., 2012. Pertuzumab and Trastuzumab in Combination with an Anthracycline-containing or an Anthracycline-free Standard Chemotherapy in the Neoadjuvant Treatment of HER2-positive Breast Cancer (TRYPHAENA). EUROPEAN JOURNAL OF CANCER, 48, S96.
  • Moyers-Ruiz, L., Hickish, T. and Thompson, S., 2012. Prospective and working memory decline as a result of impaired sleep and/or impared blood glucose in breast cancer patients during chemotherapy treatment. JOURNAL OF CLINICAL ONCOLOGY, 30 (15).
  • Hickish, T., Tseng, L.-M., Mehta, A.O., Tsang, J., Kovalenko, N., Udovitsa, D., Pelling, K., Uttenreuther-Fischer, M.M. and Huang, C.-S., 2012. LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatanib (L). JOURNAL OF CLINICAL ONCOLOGY, 30 (15).
  • Schroeder, J., Dubey, V., Hickish, T. and Cole, J., 2012. Creation of Artificial Sensation by Tactile Sensing and Intelligent Stimulation of Sensory Nerves. In: DEC Researchers Poster Conference. December 2012 Bournemouth.
  • Schroeder, J., Dubey, V., Hickish, T. and Cole, J., 2012. Multisensory Intelligent Feedback System for Sensory Substitution using Electrical Stimulation. In: DEC Researchers Poster Conference 2012 Bournemouth.
  • Hickish, T., Mehta, A., Jain, M., Huang, C.-S., Kovalenko, N., Udovitsa, D., Pemberton, K., Uttenreuther-Fischer, M. and Tseng, L.-M., 2012. LUX-Breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab and/or lapatinib. CANCER RESEARCH, 72.
  • Shipway, R., Jones, I. and Holloway, I., 2011. Healthy Options? Putting your (Running) body on the line. International Sociology of Sport Association.
  • Schroeder, J.W., Dubey, V.N., Hickish, T.F. and Cole, J., 2011. Electrocutaneous feedback system to improve the estimation of pressure applied to the foot. In: International Conference on Biomedical Electronics and Devices (BIODEVICES 2011) 26-29 January 2011 Rome, Italy.
  • Schroeder, J., Dubey, V., Hickish, T. and Cole, J., 2011. Electrocutaneous Feedback System for Patients with Loss of Sensation in their Feet. In: Salisbury FES User Day 2011 Salisbury.
  • Schroeder, J.W., Dubey, V.N., Hickish, T. and Cole, J., 2011. Electrocutaneous Feedback System to Improve the Estimation of Pressure Applied to the Foot. BIODEVICES, 386-390 SciTePress.
  • Schneeweiss, A., Hickish, T. et al., 2011. Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Concurrent with an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA). CANCER RESEARCH, 71.
  • Seymour, M.T., Hickish, T. et al., 2011. Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). JOURNAL OF CLINICAL ONCOLOGY, 29 (15).
  • Wong, R., Saffery, C., Barbachano, Y., Chau, I., Valle, J., Hickish, T., Mudan, S., Khan, A., Chua, Y.J. and Cunningham, D., 2009. BOXER: A multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection. EJC SUPPLEMENTS, 7 (2), 344-345.
  • Purandare, L., Baker, R. and Hickish, T., 2009. Can oncology nurses and other allied health professionals learn to treat post traumatic stress disorder in cancer survivors. EJC SUPPLEMENTS, 7 (2), 196.
  • Purandare, L., Hickish, T., Astras, G., Penfold, S., Thomas, F. and Kerr, D., 2009. Impaired glucose tolerance in non-diabetic women during adjuvant chemotherapy for breast cancer. EJC SUPPLEMENTS, 7 (2), 309.
  • Hickish, T., Wheatley, D., Lin, N., Carey, L., Houston, S., Mendelson, D., Solca, F., Uttenreuther-Fischer, M., Jones, H. and Winer, E., 2009. Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab. CANCER RESEARCH, 69 (24), 785S.
  • Earl, H.M., Vallier, A., Hiller, L., Fenwick, N., Iddawela, M., Hughes-Davies, L., Provenzano, E., McAdam, K., Hickish, T. and Caldas, C., 2009. Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR). JOURNAL OF CLINICAL ONCOLOGY, 27 (15).
  • Hickish, T., Wheatley, D., Lin, N., Carey, L., Houston, S., Mendelson, D., Solca, F., Uttenreuther-Fischer, M., Jones, H. and Winer, E., 2009. Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. JOURNAL OF CLINICAL ONCOLOGY, 27 (15).
  • de Gramont, A. et al., 2007. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. United States. J Clin Oncol, 25 (22), 3224-3229.
  • de Gramont, A., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Lorenzato, C. and Andre, T., 2007. FOLFOX4 in adjuvant treatment of colon cancer: Survival results from the mosaic trial. ANNALS OF ONCOLOGY, 18, VII23.
  • Chau, I., Starling, N., Cunningham, D., Oates, J., Iveson, T., Nicolson, M., Hawkins, R., Hickish, T., Seymour, M. and Norman, A., 2007. Does histology influence outcome in advanced oesophagogastric (OG) cancer? Individual patient data from 1,680 patients on three randomised controlled trials (RCT). JOURNAL OF CLINICAL ONCOLOGY, 25 (18).
  • Cassidy, J., Bjarnason, G.A., Hickish, T., Topham, C., Provencio, M., Bodoky, G., Landherr, L., Koralewski, P., Lopez-Vivanco, G. and Said, G., 2006. Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). JOURNAL OF CLINICAL ONCOLOGY, 24 (18), 147S.
  • de Gramont, A., Hickish, T. et al., 2005. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer:: Efficacy results with a median follow-up of 4 years. JOURNAL OF CLINICAL ONCOLOGY, 23 (16), 246S.
  • Hickish, T., Boni, C., Navarro, M., Tabernero, J., Topham, C., Bonetti, A., Clingan, P., Figer, A., Andre, T. and De Gramont, A., 2004. FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): Subpopulation data from the MOSAIC trial. JOURNAL OF CLINICAL ONCOLOGY, 22 (14), 274S.
  • Norman, A.R., Chau, I., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D., Shellito, P., Oates, J. and Cunningham, D., 2004. Longitudinal quality of life (QoL) and quality adjusted survival (QAS) in a randomised controlled trial (RCT) comparing bolus (24 weeks) vs. protracted venous infusion (PVI 12 weeks) 5-FU as adjuvant chemotherapy for colorectal cancer (CRC). JOURNAL OF CLINICAL ONCOLOGY, 22 (14), 276S.
  • Trumper, M.J., Norman, A.R., Ross, P.J., Cunningham, D., Hawkins, R., Seymour, M., Harper, P., Iveson, T., Nicholson, M. and Hickish, T., 2004. Patients aged 70 or older (≥ 70) with advanced oesophagogastric cancer (OGC) experience similar benefits from palliative chemotherapy compared to younger patients. JOURNAL OF CLINICAL ONCOLOGY, 22 (14), 318S.
  • Starling, N., Chau, I., Norman, A.R., Tait, D., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D. and Cunningham, D., 2004. A randomised comparison between six months of bolus fluorouracil (5-FUV leucovorin (LV) and twelve weeks of protracted venous infusion (PVI) 5-FU as adjuvant treatment in colorectal cancer: An update with 5 years' follow-up. JOURNAL OF CLINICAL ONCOLOGY, 22 (14), 250S.
  • Harper-Wynne, C., Sumpter, K., Cunningham, D., Norman, A., Oates, J., Durrant, C., Iveson, T., Nicholson, M., Hickish, T. and Hill, M., 2003. Randomised, multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: Confirmation of dose escalation. BRITISH JOURNAL OF CANCER, 88, S22.
  • Powles, R., Hickish, T. et al., 1998. A randomised trial of maintenance interferon following high dose chemotherapy in multiple myeloma: Results 51/2 years after the accrual of the last patient. BONE MARROW TRANSPLANTATION, 21, S209.
  • Powles, R., Hickish, T. et al., 1997. A randomised trial of maintenance interferon following high dose chemotherapy in multiple myeloma: Results 5 1/2 years after accrual of the last patient. BLOOD, 90 (10), 1588.
  • Raje, N., Hickish, T. et al., 1995. Peripheral blood transplants followed by maintenance interferon in myeloma. EUROPEAN JOURNAL OF CANCER, 31A, 814.
  • Singhal, S., Powles, R., Cunningham, D., Hickish, T., Middleton, G., Raje, N., Viner, C. and Mehta, J., 1995. Second autografts for relapsed myeloma. EUROPEAN JOURNAL OF CANCER, 31A, 801.
  • Raje, N., Powles, R., Hickish, T., Gore, M., Milan, S., Mehta, J., Singhal, S., Viner, C., Treleaven, J. and Cunningham, D., 1995. VAMP/C-VAMP infusional chemotherapy as induction treatment for previously untreated multiple myeloma. EUROPEAN JOURNAL OF CANCER, 31A, 799.
  • Powles, R., Raje, N., Hickish, T., Middleton, G., Milan, S., Mehta, J., Singhal, S., Viner, C., Treleaven, J. and Cunningham, D., 1995. Single centre results of therapy including autografts in previously untreated myeloma. EUROPEAN JOURNAL OF CANCER, 31A, 797.
  • Middleton, G.W., Mehta, J., Porter, H., Miller, B.C., Bell, J.A., Raje, N., Hickish, T., Shepherd, V. and Powles, R.L., 1995. Comparison of two stem cell mobilization and harvesting regimens for peripheral blood stem cell (PBSC) transplantation in multiple myeloma (MM). EUROPEAN JOURNAL OF CANCER, 31A, 246.
  • Raje, N., Powles, R., Hickish, T., Horton, C.A.P., Milan, S., Mehta, J., Singhal, S., Viner, C., Treleaven, J. and Cunningham, D., 1995. Outcome of relapsed/resistant multiple myeloma: The Royal Marsden experience. BLOOD, 86 (10), 3352.
  • Raje, N., Powles, R., Hickish, T., Milan, S., Horton, C., Mehta, J., Singhal, S., Treleaven, J. and Cunningham, D., 1995. Beta 2 microglobulin levels in patients of myeloma following high dose treatment and interferon maintenance. BLOOD, 86 (10), 3351.
  • Powles, R., Raje, N., Milan, S., Hickish, T., Mehta, J., Singhal, B., Viner, C., Treleaven, J. and Cunningham, D., 1995. Prognostic factors in multiple myeloma. BLOOD, 86 (10), 733.
  • Powles, R., Raje, N., Milan, S., Mehta, J., Singhal, S., Hickish, T., Viner, C., Treleaven, J. and Cunningham, D., 1995. Impact of induction chemotherapy followed by high dose treatment in previously untreated myeloma: A since centre experience. BLOOD, 86 (10), 732.
  • Raje, N., Powles, R., Milan, S., Hickish, T., Mehta, J., Singhal, S., Viner, C., Treleaven, J. and Cunningham, D., 1995. Induction treatment with VAMP/C-VAMP infusional chemotherapy in previously untreated myeloma. BLOOD, 86 (10), 731.
  • CLARKE, P., HICKISH, T., ROBERTSON, D., HILL, M., DISTEFANO, F. and CONNINGHAM, D., 1994. IN-VIVO EXPRESSION AND LOCALIZATION OF BHRF-1, AN EPSTEIN-BARR-VIRUS (EBV) ENCODED BCL-2 HOMOLOG. JOURNAL OF CELLULAR BIOCHEMISTRY, 230.
  • CUNNINGHAM, D., HILL, M.E., MILAN, S., MANSI, J.L., SMITH, I.E., CATOVSKY, D., GORE, M., OBRIEN, M.E.R., NICOLSON, M. and HICKISH, T., 1994. VEEP CHEMOTHERAPY FOR ADULT HODGKINS-DISEASE - ASSESSMENT OF EFFICACY AND GONADAL AND CARDIAC TOXICITY. BLOOD, 84 (10), A162.
  • CUNNINGHAM, D., OBRIEN, M.E.R., HILL, M., MILAN, S., NICOLSON, M., JONES, A.L., VINER, C. and HICKISH, T., 1994. HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANT IN HODGKINS-DISEASE - THE ROYAL-MARSDEN-HOSPITAL EXPERIENCE. BLOOD, 84 (10), A162.
  • ADSHEAD, F.J., HICKISH, T., PURVIES, H., CUNNINGHAM, D., SMITH, I.E. and MILLAR, J.L., 1991. INTERLEUKIN-3 GENE-EXPRESSION IN CYCLOPRIMED BONE-MARROW. EXPERIMENTAL HEMATOLOGY, 19 (6), 523.
  • HICKISH, T., SOUKOP, M., MILLAR, B.C., MCELWAIN, T.J. and CUNNINGHAM, D., 1990. GROWTH MODULATION OF 2 LYMPHOMA CELL-LINES BY A NOVEL CALCITRIOL ANALOG MC903. BRITISH JOURNAL OF CANCER, 62 (3), 493-494.
  • HICKISH, T., SOUKOP, M., MCELWAIN, T.J. and CUNNINGHAM, D., 1990. DISEASE ASSESSMENT WITH THE POLYMERASE CHAIN-REACTION (PCR) IN FOLLICULAR SMALL CLEAVED CELL LYMPHOMA. BRITISH JOURNAL OF CANCER, 62 (3), 485.
  • CUNNINGHAM, D., HICKISH, T., ROSIN, D., SAUVEN, P., BARON, H., FARRELL, P.J. and ISAACSON, P., 1989. PCR USED TO DETECT DISSEMINATION IN GASTRIC LYMPHOMA - IMPLICATIONS FOR TREATMENT. BRITISH JOURNAL OF CANCER, 60 (3), 447.
  • HICKISH, T., JOHNSON, M., COLSTON, K. and MAXWELL, J.D., 1986. MUSCLE STRENGTH AND VITAMIN-D STATUS IN MALE-ALCOHOLICS. CLINICAL SCIENCE, 71, P86.

Patents

PhD Students

  • Ejike Thankgod Ezeh. Web-Based Information Tool for People withAdvanced Cancer IRAS no:252843
  • Mohammad Naiseh. Explainable AI in Healthcare

External Responsibilities

  • Dorset Cancer Centre c/o Royal Bournemouth and Poole Hospitals, Consultant Medical Oncologist
  • iQHealth Tech, Medical Director

Memberships

  • Royal College of Physicians, Fellow,